Announcement • May 16
CBD Life Sciences Inc. has filed a Follow-on Equity Offering in the amount of $0.448 million. CBD Life Sciences Inc. has filed a Follow-on Equity Offering in the amount of $0.448 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 4,000,000,000
Price\Range: $0.000112
Discount Per Security: $0 Announcement • Jan 07
CBD Life Sciences, Inc. Secures Breakthrough Walmart Marketplace Approval for Mushroom Supplement, Setting the Stage for Unprecedented Growth CBD Life Sciences Inc. announce that its Mushroom Madness Rise Gummies, featuring a powerful Lion's Mane mushroom blend, have officially been approved for sale and are now available on Walmart Marketplace. This monumental approval opens the door for CBDL to tap into Walmart's expansive e-commerce ecosystem, providing a pathway to substantial revenue growth while strengthening its position in the rapidly expanding functional mushroom market. The global functional mushroom market continues to surge, projected to reach $42.4 billion by 2028, with Lion's Mane products leading the charge due to their cognitive health benefits. CBDL's Mushroom Madness Rise Gummies, formulated for focus, clarity, and enhanced mental performance, are well-positioned to meet the increasing demand for natural wellness solutions. Walmart Marketplace, recognized as one of the fastest-growing online retail platforms, boasts over 100 million monthly visitors. With third-party sellers generating substantial portions of Walmart's e-commerce revenue, the platform offers unmatched scalability and visibility for emerging brands. CBDL's entry onto Walmart Marketplace provides logistical efficiencies, enhanced consumer trust, and a direct line to an enormous, ever-expanding customer base. Industry reports indicate that third-party sellers often experience double-digit sales growth within months of launching on Walmart Marketplace. This offers CBDL an unprecedented opportunity to scale its revenues rapidly, further bolstered by Walmart's robust digital marketing support and fulfillment network. CBD Life Sciences has already achieved impressive financial growth, recording a 1405.46% increase in revenue since February 2024. The company expects Walmart Marketplace to significantly enhance its revenue stream, given the rapid consumer adoption of functional mushroom products and CBD-infused supplements. The Mushroom Madness Rise Gummies are a strategic addition to CBDL's product lineup, aligning with the company's commitment to offering scientifically formulated, high-efficacy wellness products. These gummies not only serve a growing wellness market but also position CBDL to capture a significant share of the $20 billion U.S. supplement industry. As part of its long-term strategy, CBDL plans to launch additional top-selling products on Walmart Marketplace, including its highly anticipated nano-CBD supplements and mushroom-enhanced nutritional powders. Announcement • Dec 03
CBD Life Sciences Inc. Announces New Delta-8 100MG Gummies Designed to Support Individuals Living with Alzheimer's CBD Life Sciences Inc. announced the launch of its groundbreaking Delta-8 100mg Gummies, specially formulated to support individuals living with Alzheimer's disease. These expertly crafted gummies offer gentle relief and enhanced well-being, addressing the unique needs of patients and their families navigating the challenges of neurodegenerative conditions. CBD Life Sciences' entry into this specialized segment of the $6 billion U.S. edibles market positions the company as a pioneer in creating products tailored to an underserved demographic. As the population ages and awareness of natural alternatives grows, Delta-8 products are rapidly gaining traction as effective solutions for managing symptoms associated with Alzheimer's and related conditions. A Product Born from Real Needs and Scientific Innovation: The development of these gummies is deeply rooted in the stories of CBD Life Sciences' clients, who shared how Delta-8 products have positively impacted their loved ones living with Alzheimer's. This heartfelt feedback spurred the creation of a product aimed at addressing symptoms such as anxiety, restlessness, agitation, and mood swings, all while promoting cognitive calmness and overall quality of life.Delta-8, a naturally occurring cannabinoid, is celebrated for its mild yet effective benefits. Unlike more aggressive treatments, Delta-8 provides a balance of support without overwhelming psychoactive effects, making it an ideal choice for seniors seeking natural relief. Revenue and Growth Potential: The Alzheimer's population in the United States is expected to exceed 12.7 million by 2050, creating a significant and growing demand for targeted wellness products. Early projections indicate that this product line could contribute an additional $3 million in revenue within its first year, as CBD Life Sciences continues to meet the rising interest in cannabinoid-based solutions for elderly care. The senior segment of the edibles market is rapidly emerging as a key growth area. A recent study reported a 300% increase in cannabinoid use among individuals aged 65 and older over the past decade. This demographic is increasingly turning to natural products like Delta-8 for their ability to support physical and cognitive health without the side effects often associated with pharmaceuticals. Meeting the Needs of an Underserved Market: CBD Life Sciences'Delta-8 Gummies are designed with seniors in mind. These gummies are made from all-natural ingredients, offering easy consumption, precise dosing, and a discreet form factor. Rigorous third-party testing ensures their purity, potency, and consistency, providing families and caregivers with confidence in their safety and efficacy. The gummies' formulation emphasizes cognitive support and emotional balance, helping to manage the everyday challenges of Alzheimer's while offering peace of mind to those providing care. CBD Life Sciences: Setting the Standard in Innovation: The launch of the Delta-8 Gummies for Alzheimer's marks another milestone in CBD Life Sciences' remarkable growth trajectory. Since February 2024, the company has achieved a 1405.46% increase in revenue, driven by its commitment to delivering high-quality, innovative products that resonate with consumers. This latest product also highlights the company's strategic focus on expanding its reach in the health and wellness sector, where demand for cannabinoid-based solutions continues to skyrocket. By addressing the specific needs of aging individuals and their families, CBD Life Sciences solidifies its position as a trusted leader in the industry. 
